GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Total Liabilities

Mesoblast (Mesoblast) Total Liabilities : $161.55 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Total Liabilities?

Mesoblast's Total Liabilities for the quarter that ended in Dec. 2023 was $161.55 Mil.

Mesoblast's quarterly Total Liabilities declined from Jun. 2023 ($167.58 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($161.55 Mil).

Mesoblast's annual Total Liabilities increased from Jun. 2021 ($163.32 Mil) to Jun. 2022 ($165.10 Mil) and increased from Jun. 2022 ($165.10 Mil) to Jun. 2023 ($167.58 Mil).


Mesoblast Total Liabilities Historical Data

The historical data trend for Mesoblast's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Total Liabilities Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 171.06 184.28 163.32 165.10 167.58

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.06 168.27 167.58 - 161.55

Mesoblast Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mesoblast's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.982+(106.483+16.612
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2.5+0)
=167.58

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=669.415-501.838
=167.58

Mesoblast's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=31.367+(110.614+17.073
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2.5+0)
=161.55

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=670.285-508.731
=161.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mesoblast's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.